

Int'l. Appln. No.: PCT/EP00/08784
Docket No. B45198

AI
cont'd
67. A vaccine composition according to claim 61 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.

68. A vaccine composition according to claim 62 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.

69. A vaccine composition according to claim 63 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.

70. A vaccine composition according to claim 21 comprising HSV-2 gD_t antigen and an HPV antigen chosen from the group consisting of L1, L2, E6, E7, protein D-E6, protein D-E7 or L2-E7 of HPV and optionally in addition one or more of HBsAg S antigen; EBVgp 350; VZVgpl; HAV HM-175 inactivated strain; gB685** or pp65 of HCMV and SAG1 or TG34 antigens of *Toxoplasma gondii*.

REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/EP00/08784.

Applicants have cancelled claims 1-20 and added new claims 19-70 to put the claims in conformity with U.S. practice.

No new matter has been introduced.

Respectfully submitted,



Zoltan Kerekes
Attorney for Applicant
Registration No. 38,938

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5024
Facsimile (610) 270-5090

N:\zk\apps\b45198\Preliminary Amendment.doc